Patents by Inventor Annamaria Naggi

Annamaria Naggi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10875936
    Abstract: The invention relates to N-desulfated and optionally 2-O-desulfated glycosaminoglycan derivatives, wherein at least part of the adjacent diols and OH/NH2 have been converted into the corresponding aldehyde, which aldehydes have been then reduced to the corresponding alcohol. These products are endowed with heparanase inhibitory activity and anti-tumor activity. Said glycosaminoglycan derivatives are obtained from natural or synthetic glycosaminoglycan, preferably from unfractionated heparin, low molecular weight heparins (LMWHs), heparan sulfate or derivatives thereof. The invention further relates to the process for preparation of the same and further to their use as active ingredients of medicaments, also in combination with known established drugs or treatments. The present invention further relates to a process for breaking the C2-C3 linkage of glucosamine residues of a glycosaminoglycan by oxidation of said glycosaminoglycan.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: December 29, 2020
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 10822430
    Abstract: The invention relates to glycosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glycosaminoglycan derivatives and further to their use as active ingredients of medicaments.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: November 3, 2020
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20200216577
    Abstract: A glycosaminoglycan derivative which is obtainable by a process that includes the steps of N-desulfation of from 25% to 100% of the N-sulfated residues of a glycosaminoglycan, and oxidation, by periodate at a pH of from 5.5 to 10.0, of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues, and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan, under conditions effective to convert adjacent diols and adjacent OH/NH2 to aldehydes. The process further includes reduction, by sodium borohydride, of said oxidized glycosaminoglycan, under conditions effective to convert said aldehydes to alcohols, where the glycosaminoglycan is heparin, low molecular weight heparin, heparan sulfate or fractions thereof.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20200190224
    Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 18, 2020
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20200172636
    Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20200010578
    Abstract: A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.
    Type: Application
    Filed: July 30, 2019
    Publication date: January 9, 2020
    Applicant: Chemi S.P.A.
    Inventors: Lorenzo De Ferra, Annamaria Naggi, Maurizio Zenoni, Barbara Pinto
  • Patent number: 10407515
    Abstract: A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: September 10, 2019
    Assignee: CHEMI S.P.A.
    Inventors: Lorenzo De Ferra, Annamaria Naggi, Maurizio Zenoni, Barbara Pinto
  • Publication number: 20170233501
    Abstract: The invention relates to glucosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glucosaminoglycan residues, and to the process for preparing the same. The glucosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glucosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glucosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glucosaminoglycan derivatives and further to their use as active ingredients of medicaments.
    Type: Application
    Filed: October 22, 2014
    Publication date: August 17, 2017
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20160297896
    Abstract: The invention relates to glucosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glucosaminoglycan residues, and to the process for preparing the same. The glucosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glucosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glucosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glucosaminoglycan derivatives and further to their use as active ingredients of medicaments.
    Type: Application
    Filed: October 22, 2014
    Publication date: October 13, 2016
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20160237178
    Abstract: The invention relates to N-desulfated and optionally 2-O-desulfated glucosaminoglycan derivatives, wherein at least part of the adjacent diols and OH/NH2 have been converted into the corresponding aldehyde, which aldehydes have been then reduced to the corresponding alcohol. These products are endowed with heparanase inhibitory activity and anti-tumor activity. Said glucosaminoglycan derivatives are obtained from natural or synthetic glucosaminoglycan, preferably from unfractionated heparin, low molecular weight heparins (LMWHs), heparan sulfate or derivatives thereof. The invention further relates to the process for preparation of the same and further to their use as active ingredients of medicaments, also in combination with known established drugs or treatments. The present invention further relates to a process for breaking the C2-C3 linkage of glucosamine residues of a glucosaminoglycan by oxidation of said glucosaminoglycan.
    Type: Application
    Filed: October 23, 2014
    Publication date: August 18, 2016
    Applicant: CENTRO ALTA TECNOLOGIA ISTITUTO DI RICERCHE CHIMICHE E BIOCHIMICHE "G.RONZONI" S.R.
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Publication number: 20160002365
    Abstract: A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.
    Type: Application
    Filed: January 23, 2014
    Publication date: January 7, 2016
    Inventors: Lorenzo De Ferra, Annamaria Naggi, Maurizio Zenoni, Barbara Pinto
  • Patent number: 8853387
    Abstract: The present invention is directed to sulfated oligosaccharides having 4, 5 or 6 saccharidic units and wherein a glycosidic bond between two saccharide units is substituted by a C—C bond, and wherein the sulfation degree expressed as percentage of OH groups substituted by a OSO3? group is comprised between 50 and 100%. The sulfated oligosaccharides according to the invention are useful as a drug, in particular in the treatment of angiogenesis, metastasis, and inflammation.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: October 7, 2014
    Assignee: Istituto di Ricerche Chimiche e Biochimiche “G. Ronzoni”
    Inventors: Giangiacomo Torri, Elena Vismara, Israel Vlodavsky, Annamaria Naggi
  • Publication number: 20120232263
    Abstract: The present invention is directed to sulfated oligosaccharides having 4, 5 or 6 saccharidic units and wherein a glycosidic bond between two saccharide units is substituted by a C—C bond, and wherein the sulfation degree expressed as percentage of OH groups substituted by a OSO3? group is comprised between 50 and 100%. The sulfated oligosaccharides according to the invention are useful as a drug, in particular in the treatment of angiogenesis, metastasis, and inflammation.
    Type: Application
    Filed: July 9, 2009
    Publication date: September 13, 2012
    Applicant: Istituto Scientifico Di Chimica E Biochimica "G" R
    Inventors: Giangiacomo Torri, Elena Vismara, Israel Vlodavsky, Annamaria Naggi
  • Publication number: 20080312575
    Abstract: The present invention regards the use of hemofilters for the removal of bacterial toxins (lipopolysaccharides) from the blood, said hemofilters comprising a solid support to which cyclodextrins are covalently bonded. The solid support can be a fabric or non-woven fabric or a polymeric resin obtained by means of cross-linking of the cyclodextrins with appropriate cross-linking agents, for example epichlorohydrin.
    Type: Application
    Filed: July 27, 2006
    Publication date: December 18, 2008
    Inventors: Giorgio Graziani, Annamaria Naggi, Giangiacomo Torri
  • Patent number: 7208479
    Abstract: The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: April 24, 2007
    Assignee: Baxter International, Inc.
    Inventors: Annamaria Naggi, Enrico Petrella, Giangiacomo Torri, Benito Casu
  • Patent number: 7005508
    Abstract: The present invention provides a new class of compounds presenting a high compatibility with tissues and organic fluids. Such new compounds are polysaccharides essentially formed of units of uronic acid and/or hexosamine, containing nitro groups —ONO2 covalently bonded to the saccharide structure. Preferably, the polysaccharides according to the invention are prevalently formed of disaccharide repeating units formed of uronic acid and hexosamine. These compounds, in psychological conditions, selectively release NO, allowing a reduction in the amount of NO needed to achieve a determined therapeutical effect. This result has been achieved by functionalizing polysaccharides essentially formed of units of uronic acid and/or hexosamine, with subsituents containing a ONO2 ? group.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: February 28, 2006
    Assignee: NicOx S.A.
    Inventors: Francesca Benedini, Benito Casu, Piero Del Soldato, Paolo Gresele, Annamaria Naggi, Giangiacomo Torri, Simona Venturini
  • Publication number: 20050137167
    Abstract: Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. Said glycosaminoglycan derivatives are endowed with antiangiogenic and heparanase-inhibiting activity ans are devoid of anticoagulant activity.
    Type: Application
    Filed: September 12, 2001
    Publication date: June 23, 2005
    Inventors: Benito Casu, Giangiacomo Torri, Annamaria Naggi, Claudio Pisano, Giuseppe Giannini, Sergio Penco
  • Publication number: 20040192648
    Abstract: The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.
    Type: Application
    Filed: April 14, 2004
    Publication date: September 30, 2004
    Inventors: Annamaria Naggi, Enrico Petrella, Giangiacomo Torri, Benito Casu
  • Patent number: 6770148
    Abstract: The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: August 3, 2004
    Assignee: Baxter International Inc.
    Inventors: Annamaria Naggi, Enrico Petrella, Giangiacomo Torri, Benito Casu
  • Publication number: 20040072798
    Abstract: The present invention relates to composition comprising cyclodextrins and a NO-releasing drug of formula, A-X-L-NOn, wherein A is the radical deriving from a drug; X is a divalent radical connecting A with the NO-releasing group L-NOn; L is selected from the group consisting of: O and S; n is 1 or 2.
    Type: Application
    Filed: October 15, 2003
    Publication date: April 15, 2004
    Inventors: AnnaMaria Naggi, Giangiacomo Torri, Laura Trespidi